On January 16, the clinicaltrials.gov website showed that Novartis terminated the Phase III clinical trial (CQGE031G12301 study) of immunoglobulin E (IgE) monoclonal antibody Ligelizumab for the treatment of peanut allergy.This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial that originally planned to enroll 486 patients medically diagnosed with IgE-mediated peanut allergy, aiming to evaluate the efficacy and safety of Ligelizumab (120/240mg, once monthly) compared to placebo. As of the trial termination date, the study had enrolled 211 patients.
This termination marks the second setback for Ligelizumab in the autoimmune field. In September 2023, Novartis officially halted the Phase III PEARL-PROVOKE study of Ligelizumab for the treatment of chronic inducible urticaria (CIU). The reason was that the results obtained from two Phase III studies (PEARL 1 and PEARL 2) for the treatment of chronic spontaneous urticaria (CSU) did not demonstrate significant therapeutic advantages.Ligelizumab is more effective than placebo but less effective than omalizumab.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
